Company intelligence / Profile preview

STALICLA

Ownership: Private
Development stage: Phase 2

Overview

STALICLA has completed Phase 1b for STP1 in 2022 showing good safety/tolerability, positive target engagement, and superiority in cognition endpoints in treatment versus placebo groups. The company is advancing multiple programs into Phase 2 and Phase 3 trials, including mavoglurant which has previously been tested in more than 1,800 patients with a good safety and tolerability profile.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

mavoglurant

2 more assets in the full pipeline.

Request access →

Partnerships

NovartisEvgen PharmaNational Institute on Drug Abuse/NIH (~$25 million partnership)

Beyond the preview

Go deeper on STALICLA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STALICLA.

Explore the full profile